WO2009035494A3 - Methods for producing anti-glycan antibodies, vaccines and methods for treating cancer or infectious disease - Google Patents

Methods for producing anti-glycan antibodies, vaccines and methods for treating cancer or infectious disease Download PDF

Info

Publication number
WO2009035494A3
WO2009035494A3 PCT/US2008/009045 US2008009045W WO2009035494A3 WO 2009035494 A3 WO2009035494 A3 WO 2009035494A3 US 2008009045 W US2008009045 W US 2008009045W WO 2009035494 A3 WO2009035494 A3 WO 2009035494A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
vaccines
treating cancer
producing anti
infectious disease
Prior art date
Application number
PCT/US2008/009045
Other languages
French (fr)
Other versions
WO2009035494A2 (en
Inventor
Ola Blixt
M G Finn
Eiton Kaltgrad
Original Assignee
Scripps Research Inst
Ola Blixt
M G Finn
Eiton Kaltgrad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Ola Blixt, M G Finn, Eiton Kaltgrad filed Critical Scripps Research Inst
Publication of WO2009035494A2 publication Critical patent/WO2009035494A2/en
Publication of WO2009035494A3 publication Critical patent/WO2009035494A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides vaccines that comprise protein nanoparticles at least some of which are covalently bound to glycan-containing molecules. The invention also provides methods for producing anti-glycan antibodies in a vertebrate subject. The invention further provides methods for treating cancer or infectious diseases.
PCT/US2008/009045 2007-07-30 2008-07-23 Methods for producing anti-glycan antibodies, vaccines and methods for treating cancer or infectious disease WO2009035494A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95279407P 2007-07-30 2007-07-30
US60/952,794 2007-07-30

Publications (2)

Publication Number Publication Date
WO2009035494A2 WO2009035494A2 (en) 2009-03-19
WO2009035494A3 true WO2009035494A3 (en) 2009-04-30

Family

ID=40452740

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/009045 WO2009035494A2 (en) 2007-07-30 2008-07-23 Methods for producing anti-glycan antibodies, vaccines and methods for treating cancer or infectious disease

Country Status (1)

Country Link
WO (1) WO2009035494A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49435E1 (en) 2014-11-12 2023-02-28 Seagen Inc. Glycan-interacting compounds and methods of use

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019125A2 (en) 2010-08-06 2012-02-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for prostate cancer and methods for their detection
EP3013365B1 (en) * 2013-06-26 2019-06-05 Academia Sinica Rm2 antigens and use thereof
EP3204537A4 (en) * 2014-10-10 2018-08-08 Siamab Therapeutics, Inc. Glycan analysis and profiling
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
JP2018532990A (en) * 2015-09-04 2018-11-08 オービーアイ ファーマ，インコーポレイテッド Glycan arrays and methods of use
IL258768B2 (en) 2015-11-12 2023-11-01 Siamab Therapeutics Inc Glycan-interacting compounds and methods of use
CA3019560A1 (en) 2016-03-29 2017-10-05 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
EP3445395A4 (en) 2016-04-22 2019-12-25 OBI Pharma, Inc. Cancer immunotherapy by immune activation or immune modulation via globo series antigens
KR20230117482A (en) 2016-07-27 2023-08-08 오비아이 파머 인코퍼레이티드 Immunogenic/therapeutic glycan compositions and uses thereof
EP3491026A4 (en) 2016-07-29 2020-07-29 OBI Pharma, Inc. Human antibodies, pharmaceutical compositions and methods
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. Glycan-interacting compounds and methods of use
BR112019010356A2 (en) 2016-11-21 2019-08-27 Obi Pharma Inc carbohydrate molecule, antibody-antibody conjugate (adc), composition, method for preparing the composition, method for treating cancer in an individual, method for inducing or ameliorating the immune reaction in an individual in need thereof, drug-antibody conjugate compound, use of an antibody-drug conjugate compound, method for determining therapeutic efficacy of adcc cancer cells, and method for imaging an individual
KR20240044544A (en) 2017-03-03 2024-04-04 씨젠 인크. Glycan-interacting compounds and methods of use
CN108659115B (en) * 2017-04-01 2021-07-06 武汉博仁凯润药业有限公司 Synthesis method and application of blood group antigen trisaccharide A analogue BSA derivative
CN108659059B (en) * 2017-04-01 2021-04-06 武汉博仁凯润药业有限公司 Synthesis method and application of blood group antigen A and analogues thereof
CN111278457A (en) * 2017-08-28 2020-06-12 密西根州立大学校董会 Compositions and methods for treating cancer and infection using bacteriophage and mutants thereof
CN108753733B (en) * 2018-04-11 2022-03-25 南京泰斯德生物科技有限公司 Hybridoma cell strain, anti-glycosyl monoclonal antibody generated by hybridoma cell strain, preparation method and preparation
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
CN110845587B (en) * 2019-10-15 2021-06-29 康希诺生物股份公司 Site-directed mutagenesis carrier protein and application thereof in preparation of vaccine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080895A (en) * 1985-11-25 1992-01-14 Ghen Corporation Specific antibody-containing substance from eggs and method of production and use thereof
US20070059769A1 (en) * 2004-03-05 2007-03-15 Ola Blixt High throughput glycan microarrays

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080895A (en) * 1985-11-25 1992-01-14 Ghen Corporation Specific antibody-containing substance from eggs and method of production and use thereof
US5080895B1 (en) * 1985-11-25 1998-03-10 Ghen Corp nd method of production and use thereof Specific antibody-containing substance from eggs a
US20070059769A1 (en) * 2004-03-05 2007-03-15 Ola Blixt High throughput glycan microarrays

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CONTI ET AL.: "In vitro Activity of Monoclonal and Recombinant Yeast Killer Toxin-like Antibodies Against Antibiotic-resistant Gram-positive Cocci.", MOLECULAR MEDICINE, vol. 6, no. 7, 2000, pages 613 - 619 *
GUPTA ET AL.: "Virus glycopolymer conjugates by copper(l) catalysis of atom transfer radical polymerization and azide.alkyne cycloaddition.", CHEM. COMMUN., 2005, pages 4315 - 4317 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49435E1 (en) 2014-11-12 2023-02-28 Seagen Inc. Glycan-interacting compounds and methods of use

Also Published As

Publication number Publication date
WO2009035494A2 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
WO2009035494A3 (en) Methods for producing anti-glycan antibodies, vaccines and methods for treating cancer or infectious disease
WO2008066691A3 (en) Tes7 and antibodies that bind thereto
LTPA2017011I1 (en) Antibody against PDGFR-alpha for use in the treatment of tumors
NZ593314A (en) Dual variable domain immunoglobulins and uses thereof
WO2011020783A3 (en) Targeted immunoconjugates
UA107490C2 (en) TNF-a-BINDING PROTEINS
WO2006084075A3 (en) Adam-9 modulators
WO2006084078A3 (en) Jam-3 and antibodies that bind thereto
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
IL198379A (en) Humanized antibodies and antibody fragments that specifically bind sphingosine-1-phosphate, nucleic acids encoding the same and compositions and methods for use thereof to treat disease
WO2006083852A3 (en) Luca2 and antibodies that bind thereto
WO2009083009A3 (en) Monoclonal antibodies against cd32b
EP4279140A3 (en) Human antibodies against tissue factor
WO2005103081A3 (en) Human monoclonal antibodies against cd20
WO2007031222A3 (en) Identification of tumor-associated antigens for diagnosis and therapy
WO2009061996A3 (en) Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
WO2007074193A3 (en) Method for the analysis of differential expression in colorectal cancer
WO2006076584A3 (en) Kid31 and antibodies that bind thereto
WO2013063114A8 (en) Immunobinders directed against tnf
WO2007137984A3 (en) Modified humanised anti-interleukin-18 antibodies
WO2009051220A1 (en) Antibody capable of specifically binding to aβ oligomer, and use thereof
AU2015347015A8 (en) Antibody drug conjugates
WO2009048538A3 (en) Use of anti-amyloid beta antibody in ocular diseases
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
WO2008076560A3 (en) Human monoclonal antibodies to btla and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08830244

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08830244

Country of ref document: EP

Kind code of ref document: A2